Antitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in mice

XIANGFENG HE1*, JING WANG2*, JUN DOU1*, FANGLIU YU1, KAI CAI1, XIAOLI LI1, HONGYI ZHANG1 and NING GU3

1Department of Pathogenic Biology and Immunology, Medical School; 2Department of Gynecology and Obstetrics, Zhongda Hospital; 3School of Biological Science and Medical Engineering, Southeast University, Nanjing, P.R. China

Received February 8, 2011; Accepted April 20, 2011
DOI: 10.3892/etm.2011.283

Abstract. An apoptotic tumor cell serves as a potential potent trigger for the initiation of naturally occurring tumor immunity. In the present study, a B16F10 tumor cell vaccine treated with mitoxantrone (MIT) was developed, and its antitumor effect on mice was evaluated. The results indicated that the B16F10 tumor cell vaccine treated with MIT alone or in combination with reserpine (RP) and verapamil (VP) for 12 h triggered apoptosis, and that the expression of CD80, the MHC II class molecule, NKG2D and its ligand were significantly increased compared to the expression levels in the control group. The tumor vaccine immunogenicity was significantly enhanced in the vaccinated mice, resulting in augmented cytotoxicity of splenocytes and NK cells as well as the splenocyte proliferative response compared to the control group mice. Notably, the mice vaccinated with the B16F10 tumor cell vaccine treated with MIT, RP and VP did not generate tumors only after 60 days into the observation, but the mice also generated a powerful immune prophylactic efficiency against the B16F10 tumor cell challenge. These findings demonstrated the safety and efficacy of the B16F10 tumor cell vaccine treated with MIT alone or in combination with RP and VP in the murine model, and suggest that an apoptotic tumor cell vaccine modeled on naturally occurring tumor immune responses in vivo may provide a safe and immunogenic tumor vaccine for potential applications in humans.

Introduction

Tumor cell vaccines are a promising emerging treatment option to cure tumors, although novel immunotherapeutic options for all types of tumors have been recently developed. Apoptotic tumor cells can be recognized and eliminated by the power of the immune response, which has resulted in the intense interest in the development of tumor cell vaccines transfected with DNA containing target genes, immune molecules or treated using different biological methods (e.g., freeze-thawing, large amounts of ultraviolet light, γ-irradiation or anticancer drugs). These tumor cell vaccines are currently being evaluated as prophylactic and therapeutic vaccines for tumors (1,2).

Mitoxantrone (MIT), a non-cell cycle-specific anthraquinone anticancer drug, induces cell apoptosis by inhibiting DNA synthesis. Treatment of tumor cells with MIT was found to result in translocation of calreticulin from endoplasmic reticulum to the cell surface along with cell apoptosis, which leads to the increased immunogenicity of tumor cells. These MIT-treated apoptotic B16F10 cells may be used as a type of tumor cell vaccine to initiate an effective antitumor immune response in mice (3). The drug-treating tumor cells inoculated into mice are able to be effectively recognized by dendritic cells (DCs) and stimulate the immune system to effectively eliminate tumor cells that are resistant to chemotherapeutic drugs (4). However, certain tumor cells exhibiting a high degree of malignancy, such as murine melanoma B16F10 cells, express ATP-binding cassette (ABC) transporter proteins, such as multidrug resistance protein 1 (MDR1 or ABCB1), the multidrug resistance protein 1, (MRP1 or ABCC1), ABCB5 and breast cancer resistance protein 1 (ABCG2/BCRP1) (5-7). These multidrug-resistant proteins are able to rapidly 'pump out' anticancer drug from tumor cells, so that a few of the tumor cells that were treated with anticancer drugs survive and generate tumors in vivo. In order to assess the feasibility, safety and immunogenicity of tumor cell vaccines, efforts are ongoing.

Verapamil (VP) and reserpine (RP) are known inhibitors of efflux pumps and block the function of multidrug-resistant proteins, resulting in the retention of anticancer drugs in the tumor cells (8-10). In the present study, B16F10 cells were pretreated with VP and RP to inhibit the activity of the efflux of MIT in the cells, and then B16F10 cells were treated with MIT to cause retention of MIT in the cells. The treated tumor cells gradually underwent apoptosis in the experimental mice and were phagocytosed by autologous DCs. This finally induced
mice to generate the initiation of naturally occurring antitumor immunity that partly prevented tumor growth. Here, we report the safety and immunogenicity of an apoptotic B16F10 tumor cell vaccine in a controlled study of C57BL/6 mice.

Materials and methods

Animals and cells. Female C57BL/6 mice, 6–8 weeks of age, 18–20 g, were obtained from the University of Yangzhou, China. All mice were housed under pathogen-free conditions, and the experiments were performed in compliance with the Guidelines of the Animal Research Ethics Board of Southeast University. The B16F10 murine melanoma cell line is syngeneic in C57Bl/6 mice and was a gift from Professor Pingsheng Chen, Medical School, Southeast University; the YAC-1 cell line (Mo-  

Animal experiments. In the safety experiment, C57BL/6 mice were first divided into three experimental groups and one control group. Each mouse was subcutaneously (s.c.) immunized in the abdominal region with 2x10^5, 5x10^6 or 1x10^7 B16F10 cells treated with MIT for 12 h, or 1x10^7 wild-type B16F10 cells as control. C57BL/6 mice were secondly divided into four experimental groups and one control group. Each mouse was s.c. immunized in the abdominal region with 1x10^6 B16F10 cells treated with MIT in combination with RP and VP for 12 h, or 1x10^6 wild-type B16F10 cells as control.

In the antitumor effect experiment, C57BL/6 mice were randomly divided into the experimental, the B16F10 cell and the PBS control groups. Each mouse was immunized s.c. in the abdominal region, respectively, with a vaccine of 5x10^5, 5x10^6 or 1x10^7 B16F10 tumor cells treated with MIT in combination with RP and VP for 12 h or 1x10^7 wild-type B16F10 cells as control.

B16F10 cells (5x10^6) treated with MIT alone or in combination with RP and VP were inoculated into 24-well plates in RPMI-1640 medium. The drugs were applied at concentrations as follows: 2 µg/ml MIT, 2 µg/ml MIT + 1 µg/ml RP, 2 µg/ml MIT + 1 µg/ml VP and 2 µg/ml MIT in combination with 1 µg/ml RP and 1 µg/ml VP, respectively. The samples at different time points (0, 12, 48, 96 and 144 h) were obtained with 1 µg/ml RP and 1 µg/ml VP, respectively. The anti-sense was 5'-GGACTTGAGCAAGATGG-3' and the anti-sense was 5'-AGACGTGTGGGCGCATACG-3'. Total cellular RNA was extracted from 1x10^6 B16F10 cells by using the RNAeasy Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. cDNA was synthesized with the reverse Super-Script Choice System (Invitrogen, Carlsbad, CA, USA). cDNAs of ABCB1 and β-actin were respectively amplified by PCR with the above-mentioned primers.

Detection of side population cells in B16F10 cells. B16F10 cells, 70% confluent in complete medium, were transferred to 6-well plates for 24 h, and Hoechst 33342 (5 µg/ml) was added to each well and maintained for 1 min at room temperature. The cells were then washed with PBS three times and subsequently observed under a light and fluorescence microscope, respectively.

Effect of RP and VP on the exclusion rate of MIT in B16F10 cells. B16F10 cells (70% confluent in complete medium) were transferred to 6-well plates for 24 h and then 1 µg/ml RP and 1 µg/ml VP were added to the wells for 30 min to inhibit ABCB1 efflux pumps. Then, 2 µg/ml MIT was added to the wells and cultured for another 12 h. Next, the cells were washed with PBS three times and then fixed using 1% paraformaldehyde. The exclusion rate of MIT was detected by fluorescence confocal microscopy under 488-nm excitation light and 675-nm emission light.

Assays of splenocyte cytotoxicity and splenocyte proliferative response. Two weeks after the final immunization, 10 mice were sacrificed to detect immune efficiency. Splenocytes (5x10^6) were prepared from the C57BL/6 mice immunized with the 5x10^5 B16F10 tumor cell vaccine treated with MIT in combination with RP and VP. The harvested splenocytes were labeled with 0.5 mM 5- (and 6)-carboxy-fluorescein diacetate succinimidyl ester (CFSE; 20 µg/ml) at 37°C for 15 min. After the incubation, the splenocytes were washed twice in PBS containing 5% fetal bovine serum to sequester any free CFSE that had failed to diffuse into the cells. Murine splenocytes (2x10^4) were resuspended in 10% RPMI medium in 6-well plates and then incubated with 2x10^4 B16F10 cells inactivated with mitomycin c
In the present study, we first assessed the safety of the B16F10 tumor cell vaccine treated with MIT. After the B16F10 cells were treated with 2 µg/ml MIT for 12 h, the cells began to undergo apoptosis and were then injected into the mice (10 mice/group). Measurable tumors were detected in the mice injected with the MIT-treated 1x10⁶ B16F10 cells on day 15 or on day 20 (in the 2x10⁶ B16F10 cell group) or on day 10 (in the 1x10⁶ wild-type B16F10 cell group), respectively. From the tumorigenesis data, 7 out of 10 mice inoculated with the MIT-treated 1x10⁶ tumor vaccine, 4 out of 10 mice inoculated with the MIT-treated 5x10⁵ tumor vaccine, and 1 out of 10 mice inoculated with MIT-treated 2x10⁵ B16F10 cells, respectively, formed tumors up until 60 days into the observation. The results indicated that the MIT-treated 2x10⁵ B16F10 cells still possessed tumorigenic potential in C57BL/6 mice in spite of only 1 out of 10 mice developing tumors (Fig. 1A). In the subsequent safety experiment, the B16F10 cells were pretreated with 1 µg/ml RP or/and 1 µg/ml VP and then the cells were re-treated with 2 µg/ml MIT. The B16F10 cell vaccine treated with MIT + RP + VP was complete safety as all 10 mice did not develop tumors until 60 days into the observation. However, in regards to the mice treated with MIT + RP or MIT + VP, 2 out of 10 or 4 out of 10 mice, respectively, still developed tumors (Fig. 1B). Next, we evaluated the antitumor efficacy in mice inoculated with the preparation of 5x10⁵ B16F10 cells treated with MIT in combination with RP and VP as a tumor cell vaccine. Fig. 1C shows that 6 out of 10 mice immunized with the treated 1x10⁶ B16F10 tumor cell vaccine twice and challenged by 1x10⁵ B16F10 cells formed tumors on days 12, 16, 25, 30, 30 and 35. The remaining 4 mice did not form tumors throughout the 60-day observation. However, all 10 mice formed tumors in less than 14 days when immunized with PBS or in less than 27 days when immunized with 5x10⁵ B16F10 cells inactivated with mitomycin C twice and challenged by 1x10⁵ B16F10 cells. These findings demonstrate that the B16F10 tumor cell vaccine treated with MIT in combination with RP and VP is not only safe, but induces mice to generate a powerful and efficacious antitumor immune response.

ELISA for IFN-γ. The serum IFN-γ level was measured using a commercially available enzyme linked-immunosorbent assay according to the manufacturer's protocol (eBioscience) (2,11).

Statistical analysis. For each group of mice, data were represented as the mean value of each group and its associated standard deviation. The Student's t-test for two-group comparison and Bonferroni correction for multiple comparisons were used to determine significant differences. p<0.05 was considered statistically significant.

Results

Safety of the B16F10 tumor cell vaccine and its antitumor efficacy in mice. In the present study, we first assessed the safety of the B16F10 tumor cell vaccine treated with MIT. After the B16F10 cells were treated with 2 µg/ml MIT for 12 h, the cells began to undergo apoptosis and were then injected into the mice (10 mice/group). Measurable tumors were detected in the mice injected with the MIT-treated 1x10⁶ or 5x10⁵ B16F10 cells on day 15 or on day 20 (in the 2x10⁶ B16F10 cell group) or on day 10 (in the 1x10⁶ wild-type B16F10 cell group), respectively. From the tumorigenesis data, 7 out of 10 mice inoculated with the MIT-treated 1x10⁶ tumor vaccine, 4 out of 10 mice inoculated with the MIT-treated 5x10⁵ tumor vaccine, and 1 out of 10 mice inoculated with MIT-treated 2x10⁵ B16F10 cells, respectively, formed tumors up until 60 days into the observation. The results indicated that the MIT-treated 2x10⁵ B16F10 cells still possessed tumorigenic potential in C57BL/6 mice in spite of only 1 out of 10 mice developing tumors (Fig. 1A). In the subsequent safety experiment, the B16F10 cells were pretreated with 1 µg/ml RP or/and 1 µg/ml VP and then the cells were re-treated with 2 µg/ml MIT. The B16F10 cell vaccine treated with MIT + RP + VP was complete safety as all 10 mice did not develop tumors until 60 days into the observation. However, in regards to the mice treated with MIT + RP or MIT + VP, 2 out of 10 or

Detection of the ABCB1 gene, side population cells and exclusion rate of MIT in B16F10 cells. From the tumorigenesis data, we found that the MIT-treated B16F10 cells still exhibited tumorigenicity in mice. The main reasons may be that the B16F10 cells are malignant cells and have the ability to discharge MIT from the treated B16F10 cells by ABC transporter proteins. Thus, a few of the B16F10 cells did not undergo apoptosis after the MIT treatment. Since ABCB1 is one of the ABC transporter proteins, we aimed to ascertain whether the ABCB1 gene was present in the B16F10 cells. The RT-PCR result demonstrated expression of the ABCB1 gene (Fig. 3A). It is also known that side population (SP) cells, also termed ‘dull cells’, usually represent only a small fraction of the whole cell population that are identified by efflux of Hoechst dye through ABC transporter proteins, and are present in virtually all malignant cells and a part of normal tissues (21,22). Thus, we further detected SP cells in the B16F10 cells. A small fraction of SP cells (Fig. 2B, arrows) existed in the B16F10 cells, nevertheless, the SP cells were invisible in the B16F10 cells after the cells were treated with RP and the VP (Fig. 2C). This was due to the blockage of efflux pumps of ABCB1 by RP and the VP. As a result, the SP cells were not observed under a fluorescence
microscope since the Hoechst 33342 stain was retained in the B16F10 cells, which made the SP cells were stained and did not be ‘dull cells’. To further assess the function of the inhibition of ABCB1 efflux pumps by RP and the VP, we subsequently assessed the MIT exclusion ratio in the B16F10 cells. As shown in Fig. 2D, the ability to exclude MIT was statistically significantly decreased when the B16F10 cells were concurrently treated with MIT, VP and RP in contrast to the ability of MIT-treated (p<0.003), MIT + VP-treated (p<0.03) and MIT + RP-treated B16F10 cells (p<0.05). The results suggest that RP and VP block the function of ABCB1 efflux of MIT and assist MIT in further inducing B16F10 cell apoptosis.

Detection of apoptotic B16F10 cells treated with MIT in combination with RP and VP as well as molecular expression. Fig. 3A shows that B16F10 cells gradually experienced apoptosis 48 h after treatment with MIT in combination with RP and VP. In viable apoptotic cells, the cell membrane began to shrink and became a green color. In non-viable apoptotic cells (after 96 h), the cell nucleus became a red color, while the cell membrane remained green. When apoptotic B16F10 cells were cultured with the autologous DCs from mouse bone marrow for 72 h, the DCs ingested more apoptotic bodies (Fig. 3B) compared to the control DCs (Fig. 3C). In order to visualize the state of phagocytic apoptotic bodies, DiI-labeled apoptotic B16F10 cells were incubated with the DCs stained for FITC-conjugated CD11c. It was found that the apoptotic B16F10 cells (red) were detected inside DCs (green) by fluorescence microscope analysis (Fig. 3D). As the capability of phagocytic apoptotic B16F10 cells was increased, the molecular expression of CD80 (Fig. 3E) and MHC class II (Fig. 3F) was statistically significantly increased on the surface of DCs, respectively, compared to that of DCs incubated with wild-type B16F10 cells (p<0.05 or <0.01). The increase in the molecular expression suggested that DCs underwent a maturation process and served as a potential trigger for the initiation of a immune response in vivo.

In addition, the expression of the NKG2D ligand in MIT-treated apoptotic B16F10 cells (Fig. 3F) and the expression of NKG2D in the NK1.1+ cells from the vaccinated mice (Fig. 3G) were statistically significantly increased compared to those of wild-type B16F10 cells, respectively. This data demonstrated that the apoptotic B16F10 tumor cells promoted DC maturation as well as enhanced the expression of NKG2D and its ligand.

Immune efficacy induced by the B16F10 tumor cell vaccine treated with MIT in combination with RP and VP. As shown in Fig. 4B and C, the B16F10 tumor cell vaccine treated with MIT in combination with RP and VP induced the mice to elicit a powerful prophylactic efficiency against B16F10 cell challenge. To investigate the main mechanism of the antitumor effect induced by the B16F10 tumor cell vaccine, we assessed the cytotoxicity of splenocytes and NK cells and detected the splenocyte proliferative response and the serum level of IFN-γ. Data showed that the cytotoxic activity of splenocytes and NK cells was statistically significantly increased (p<0.01 or <0.05), respectively, compared to the control mice (Fig. 4A). This was also verified by the splenocyte proliferative response and the serum level of IFN-γ (Fig. 4B and C). The results of the immunological experiment suggest that the B16F10 tumor cell vaccine enhanced the cellular immune function in vaccinated mice, which may be a major mechanism of the antitumor efficacy induced by the B16F10 tumor cell vaccine treated with MIT + RP and VP.

Discussion

Several studies have revealed that the use of apoptotic cells in vaccines may serve as a potent source of antigens for stimulating host immune responses in vivo (3,23,24). In the present study, the anthracycline drug MIT was used to induce B16F10 cell apoptosis that was immunized into mice to assess the safety of a vaccine of MIT-treated tumor cells. However, the result was not satisfactory as these treated tumor cells retained tumorigenic potential in the C57BL/6 murine model (Fig. 1A).

The goal of tumor vaccine development is its safeness and effectiveness. Therefore, the reasons why MIT-treated tumor cells possess tumorigenic potential were investigated. The ABCB1 transporter protein (Fig. 2A) and a few SP cells (Fig. 2B) were found in the B16F10 cells. Approximately 0.3% MIT was able to be discarded from the MIT-treated tumor cells through SP cells via the ABCB1 transporter protein. Thus, a few B16F10 cells did not undergo the apoptotic process and retained tumorigenic potential in vivo. For this reasons, the B16F10 cells were pretreated with RP and VP to block the function of efflux pumps, and then were retreated with MIT. As a result, SP cells disappeared in the B16F10 cells (Fig. 2C), MIT was almost completely maintained in the treated tumor cells (Fig. 2D) and there was nearly complete apoptosis at 144 h (Fig. 3A). The apoptotic B16F10 cells were utilized as
a tumor vaccine to vaccinate the mice twice and then B16F10 cell challenge. The B16F10 tumor cell vaccine treated with MIT in combination with RP and VP was not only completely safe (Fig. 1B), but induced an obvious prophylactic effect against B16F10 cell attack in the murine model (Fig. 1C).

Subsequently, the possible mechanism of antitumor efficacy induced by the preparation of the B16F10 tumor cell vaccine in mice was investigated. It is known that B16F10 tumor cells exhibit low immunogenicity and do not easily elicit an antitumor immune response in murine models. However, apoptotic B16F10 tumor cells induced a strong immune response in the tumor-bearing mice (3,25). For this reason, we induced B16F10 cell apoptosis by using the anthraquinone anticancer drug MIT, in combination with RP and VP (Fig. 3A). When the autologous DCs from mouse bone marrow were concurrently incubated with the apoptotic B16F10 cells for 3 days, the immature DCs developed into mature DCs, resulting in the increased molecular expression of CD80 and MHC class II by flow cytometry. (G) Expression of the NKG2D ligand was significantly increased in the B16F10 cells treated with MIT for 144 h compared to that of the control B16F10 cells. Expression of NKG2D (MFI) was significantly increased in NK cells in (H) the mice immunized with the treated tumor cell vaccine (p<0.05) in contrast to that of (I) the control cells. One representative experiment was repeated three times. MFI, mean fluorescence intensity. ***p<0.001, **p<0.01, *p<0.05.
epitope in the context of both class II and I MHC to prime lymphocytes, which are specialized functions of DCs (25,26). Therefore, the apoptotic B16F10 cells may act as a tumor cell vaccine that may elicit lymphocyte activation via the above-mentioned mature DCs in vivo. In addition, the NKG2D receptor (Fig. 3H) and NKG2D ligand (Fig. 3G) were highly expressed in the NK and apoptotic tumor cells, respectively. The NKG2D immunoreceptor interacting with the NKG2D ligand serves as one of the most potent activating receptor and ligand for effector NK cells, playing an important role in the immunosurveillance of tumors (27). Although we did not detect the translocation of calreticulin from endoplasmic reticulum to the cell surface, this mechanism has been confirmed by other researchers (3,4,28,29). Accordingly, we assumed that the treatment of a tumor cell vaccine with MIT would cause cell apoptosis resulting in a calreticulin coating on the surface of apoptotic cells for recognition and uptake by DCs. The presented apoptotic cells by DCs may include a predominant antigen for eliciting lymphocytes in immunized mice to generate strong immune responses (23,30). Consequently, the cytotoxicity of splenocytes and NK cells as well as the splenocyte proliferative response and the serum IFN-γ level were markedly enhanced compared to the control mouse group (Fig. 4).

In conclusion, this study demonstrated that the B16F10 tumor cell vaccine treated with MIP in combination with RP and VP was safe and efficient. The apoptotic tumor cells facilitated DC maturation, leading to the activation of lymphocytes in the vaccinated mice. The immune efficacy induced by the treated tumor cell vaccine exhibited powerful prevention against B16F10 cell challenge in the murine model. These data provide knowledge that may be useful for developing an effective B16F10 tumor cell vaccine for the treatment of melanoma patients in clinical trials.

Acknowledgements

The authors wish to extend gratitude to Dr Lili Chu and Dr Fengshu Zhao for the expert administrative assistance. This study was partly supported by the National Natural Science Foundation of China (no. 81071769) and in part by the 973 Program of China (no. 2011CB933500).

References